Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the hikma website.
I’ll take anything with 2 digits before the decimal to get me out of this mess!
Thanks BB
Please don’t post this without a link or proof. Also, if this is false, this is the easiest way for the whole board to turn on you.
I believe its 2029 in the US
Can you copy and paste the text here ? Article is locked
I pulled this from another user on stock twits , its interesting.
https://www.bloomberg.com/news/articles/2020-10-02/glaxo-wins-reinstatement-of-235-million-verdict-against-teva
I was thinking the same thing. I have to be missing something here
I agree with you, hopefully we will get our second chance. Thanks for spreading optimism. Best of luck!
Well I guess what I really meant was i’m sure they have a better idea than us regarding AMRN’s true plan. For now, I’m forced to keep the faith—the drug is extremely underrated.
I’m only saying if because someone posted earlier here that they were close to certain. I don’t really understand how they came to that conclusion.
As an outsider, I see the same two possibilities on the horizon as you. But, BB ? Obviously, they are much smarter than you and I.
IF they bailed entirely at any point this quarter, they clearly don’t see the price rising above $8 any time soon. Just my layman take.
With all due respect, please help me understand how you still would believe there is so much to gain if BB liquidated their entire position. I am long here, I haven’t sold a single share but I think if BB is entirely out, we are toast.
Huh?
Can you provide the link where it says Hikma is obtaining their API from this company ?
In that case you’re right. If they can’t manage script growth here in the US, I have no clue what makes them believe they can handle it in Europe. With that said, we do obviously have to account for covid hindering growth.
Labor day week scripts
Ironically, I don’t think we want to see any open market purchases. That would eliminate the possibility of current negotiations for the company to be sold.
I hopped in yesterday at .70, very strange things don’t usually go my way like this ...............
Ah then in that case, i agree with your take entirely.
Makes no sense to me, but I think/hope there is just too much going on behind the scenes to speculate. I just hope there’s more clarity within the next month. My patience is running extremely thin with AMRN.
It was on q2 conference call, so before appeal loss. Many suspect it was to keep BO possibility in tact, but that’s thinking too logically for AMRN in my opinion.
He already announced that.
Worth a shot, keep us posted!
By clicking on that link, you may not find the quote i referenced, but if you paste the article title in google, google should include the quote i referenced in their summary
https://www.lexology.com/library/detail.aspx?g=43c5ddb8-e892-4995-9bc7-d04a127389e7
I believe raf’s reference was due to where Kennedy lives
An article from 2011 that I cannot access in full seems to refer to Nevada as...
“a just, speedy, and inexpensive determination of their patent rights.”
I don’t have any idea. My best guess would be along the lines of being that the authorized generic would be identical to the brand name drug, maybe an insurance company views the roughly $20 difference btwn the authorized generic and regular generic in the example as “worth it” ?
I imagine i’m way off, but seems logical to me.
Reuters listed Lee M. Stern as a person to direct shareholder inquiries to...? Maybe another ear to voice opinions to?
Amarin Contact Information
Investor Inquiries:
Elisabeth Schwartz
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
IR@amarincorp.com (investor inquiries)
Lee M. Stern
Solebury Trout
In U.S.: +1 (646) 378-2992
lstern@soleburytrout.com
Media Inquiries:
Alina Kolomeyer
Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
PR@amarincorp.com (media inquiries)
Guess that could be it
The new DTC ad just posted today on youtube has almost 130k views already... does that sound like an abnormally high amount of views for those more familiar with youtube ?
Only reason i bring up 2-1 as opposed to 0-3 has to do with odds of en banc being granted, but i’m on your side, John. Your argument makes sense to me.
I would have never guessed that to be the case. That said, of those 14, i have to imagine damn near all of them were 2-1 on appeal decision.
I guess a better question would be who exactly sits down to review whether to grant or deny en banc? Is it all 12 judges that vote on it ?
There is a (slim) chance they did not want to show their hand to the generics too early
Could there be some type of remedy for this disaster that AMRN has kept a secret? The communication from this company has been abysmal.
John, i’m sorry if you touched on this earlier. Judging by how the CAFC judges seemed to carelessly handle this appeal, what gives you confidence that the legal system will review this rule 36 affirm carefully for potential en banc review? After seeing how this all played out, seems like the fix was in.
The district court judge would have to agree to vacate her decision. I am a layman, but I see almost no chance of H&R settling at this point.